TABLE 1.
Subjects | 30-day mortality# | p-value | OR (95% CI) | |
Age years | ||||
18–59 | 7420 (28) | 4.6 | <0.001 | 1 |
60–69 | 10 555 (40) | 6.0 | 1.3 (1.2–1.5) | |
70–79 | 7163 (27) | 7.5 | 1.7 (1.5–2.0) | |
≥80 | 1139 (4) | 9.8 | 2.3 (1.8–2.9) | |
Year of diagnosis | ||||
2010 | 4253 (16) | 6.4 | 0.15 | |
2011 | 4254 (16) | 7.0 | ||
2012 | 4389 (17) | 6.2 | ||
2013 | 4364 (17) | 6.1 | ||
2014 | 4475 (17) | 5.6 | ||
2015 | 4542 (17) | 6.0 | ||
Sex | ||||
Male | 14 719 (56) | 6.5 | 0.03 | |
Female | 11 558 (44) | 5.8 | ||
Stage | ||||
IIIA | 4515 (17) | 2.5 | <0.001 | ¶ |
IIIB | 4330 (16) | 3.6 | ||
IV | 17 432 (66) | 7.8 | ||
Histology | ||||
Adenocarcinoma | 10 883 (41) | 5.3 | <0.001 | 1 |
Squamous | 4414 (17) | 4.4 | 1.1 (0.9–1.3) | |
Other NSCLC | 3770 (14) | 6.5 | 1.4 (1.2–1.6) | |
SCLC | 7210 (27) | 8.5 | 1.7 (1.5–1.9) | |
Metastatic sites involved n | ||||
0 | 8841 (34) | 3.0 | <0.001 | 1 |
1 | 9182 (35) | 6.0 | 2.1 (1.8–2.4) | |
2 | 4865 (19) | 8.6 | 3.0 (2.6–3.5) | |
≥3 | 3389 (13) | 11.5 | 4.3 (3.7–5.1) | |
Type of treatment | ||||
Chemotherapy | 25 010 (95) | 6.1 | <0.001 | 1 |
Targeted | 1267 (5) | 8.6 | 1.3 (1.1–1.6) |
Data are presented as n (%) or %, unless otherwise stated. NSCLC: non-small cell lung cancer; SCLC: small cell lung cancer. #: as percentage of the population within this group; ¶: not included in multivariable analysis to avoid collinearity.